How Orca-T May Transform Blood Cancer Treatment During Transplant

As treatment options for acute myeloid leukemia (AML) evolve, new therapies could change the patient experience around allogeneic stem cell transplant. CURE sat down with Dr. Gwen Nichols, chief medical officer of Blood Cancer United, to discuss the potential impact of Orca-T, a therapy under consideration for approval.

Orca-T is an investigational T-cell therapy that is being studied in Precision-T, a national clinical trial; Orca-T is being evaluated against conventional stem cell transplant in patients with acute leukemias and high-risk blood disorders. Orca-T uses specially purified immune cells to help prevent graft-versus-host disease while supporting transplant recovery. The therapy has received special FDA designations and is under priority review, with a decision expected in April 2026, according to a news release from Orca Bio.

Nichols shares her perspective on how Orca‑T might influence treatment decisions, patient outcomes, and quality of life for those undergoing transplant.

CURE: For patients facing AML or considering allogeneic stem cell transplant, how could the potential approval of Orca-T change the treatment experience compared with standard stem cell transplant?

Nichols: One of the biggest issues around allogeneic stem cell transplant is graft-versus-host disease. While a small amount may benefit survival, it significantly affects quality of life and can determine whether a transplant is offered. If Orca‑T shows strong results, it could influence both doctors’ willingness to offer transplant and patients’ willingness to accept it. Most importantly, it doesn’t appear to impact survival.

Is there anything you want to add about other benefits patients might see in terms of recovery, side effects, or quality of life?

Graft-versus-host disease can take many forms. The new immune system may recognize the host as foreign, causing issues ranging from mild fevers and chills to severe skin rashes or life-threatening effects. In the GI tract, patients can experience diarrhea and inability to eat. It can affect the oral mucosa and impede normal cell recovery. These complications lead to both early and late morbidity and mortality, including death from infection or failure to recover.

Long-term, graft-versus-host disease can impair the immune system, skin integrity, and mobility, often requiring prolonged immunosuppressive therapy. Even after blood cancer is cured, these effects can be devastating. Better control of graft-versus-host disease is an important step forward for patients undergoing transplant.

Moving forward, how might access to Orca-T differ for patients in urban versus rural settings, and what can patients do to ensure they’re aware of this option?

Rural versus urban differences aren’t really about Orca‑T, because transplant centers are mostly in urban areas. Transplant is rarely performed in small community settings. The bigger issue is whether patients are referred to those centers, which depends on insurance and location. Transplant often requires hospitalization for a month and support from a caregiver. Not everyone has adequate insurance or assistance. If Orca‑T expands transplant eligibility, disparities between patients with supportive insurance and those without may become more apparent.

In your experience, what questions do patients commonly have when learning about new therapies like Orca‑T, and how would you help them feel supported?

Patients often ask whether a new therapy affects their chance of cure. Current data suggest it does not. Another common question is whether Orca‑T

adds side effects beyond those of transplant. The side effect profile hasn’t diminished the observed benefits. When patients understand the potential for graft-versus-host disease and its impact on quality of life post-transplant, they can weigh these factors when deciding whether to accept Orca‑T.

Winding down, is there anything you want to add about the potential long-term impact of this therapy if approved by the FDA?

Long-term data aren’t available yet, but fewer cases of graft-versus-host disease should mean fewer patients develop chronic transplant-related illness. This could improve both quantity and quality of survival.

Is there anything you want to add?

Yes. I encourage patients to explore the resources on our website about transplant, new therapies, and graft-versus-host disease. Reading and reflecting on this information provides context that a single conversation with a doctor cannot.

Blood Cancer United offers comprehensive resources for transplant, the underlying disease, and graft-versus-host disease, which can help patients and caregivers navigate these complex decisions.

Transcript has been edited for clarity and conciseness.

References

1. “Orca Bio Announces Orca-T® Phase 3 Data Published in Blood Demonstrate Significant Improvement in Survival Free from Chronic Graft versus Host Disease in Patients with Hematological Malignancies,” by Orca Bio. News release; Dec. 15, 2025.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.